- Record Total Revenues of $59.0 Million, Up 46 Percent Over Third Quarter
2006 - Third Quarter EPS of $0.70 per Basic Share, or $0.66 per Diluted Share - Third Quarter EBITDASO of $1.26 per Basic Share, or $1.19 per Diluted
SILVER SPRING, Md., Nov. 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2007.
Total revenues for the third quarter of 2007 were $59.0 million, up 46% from $40.4 million for the third quarter of 2006. Pro forma earnings corresponding to our Company-wide Milestone measuring GAAP earnings before income taxes, depreciation, amortization and stock option expenses (EBITDASO), were $26.6 million for the third quarter of 2007, up 35% from $19.7 million for the third quarter of 2006. Net income for the third quarter of 2007 was $14.8 million, or $0.70 per basic share, up 74% from $8.5 million, or $0.37 per basic share, in the third quarter of 2006. Gross margins from sales were $52.2 million in the third quarter of 2007, as compared to $36.2 million in the third quarter of 2006. The increases in revenues and gross margins resulted primarily from growth in sales of our lead product, Remodulin.
"It is pretty gratifying for us to be on the line of approximately 40%
annual growth in revenues for almost five years now," said Martine
Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive
Officer. "Our trailing twelve month revenues of $196.9 million are 37%
above that of the preceding period. Plus, this is our 13th profitable
quarter overall, and our 14th straight profitable quarter disregarding
|SOURCE United Therapeutics Corporation|
Copyright©2007 PR Newswire.
All rights reserved